Our Board

Science by itself is not sufficient for success: our board has been here to help Scipio grow in the right direction and secure its promising future.

Stuart Edelstein
Stuart Edelstein

Stuart Edelstein

Chairman
Stuart is a world-renowned biophysicist. A foreign associate of the French Academy of Science, his academic curriculum includes professorships at Cornell University (NY, USA), University of Geneva (Switzerland), ENS (Paris, France) and the Collège de France. Stuart also has start-up experience as co-founder of a publicly listed biotech company.
Philippe Tramoy
Philippe Tramoy

Philippe Tramoy

Member of the Board
Philippe, a partner at Seventure Partners, is in charge of life siences investments for the Quadrivium I fund. He started his career as a Project Manager and Director of Business Development Europe in the Rhodia group and later founded a market and business intelligence company, CBDMT – Market & Business Intelligence, which he managed for 10 years prior to joining Seventure.
Arnaud Autret
Arnaud Autret

Arnaud Autret

Member of the Board
Arnaud is Investment Principal at M Ventures and based in Amsterdam. He received a PhD in immunology from the Pasteur Institute and a MSc in Finance from ESCP Europe. He started his career at KPMG as a Financial Auditor in the Healthcare business unit. He then worked at Seventure Partners as Senior Associate where he invested in Life Sciences companies.
Prof Stéphane Le Crom
Prof Stéphane Le Crom

Prof Stéphane Le Crom

Independent Member of the Board
Stéphane is the head of the Omics network of the Université Pierre et Marie Curie (UPMC, Paris, France) and of the genomics facility at the École normale supérieure (Paris). In addition to these positions, Stéphane teaches genomics at the UPMC, and heads a research team dedicated to data analysis from high-throughput genomics studies.
Frank Hensel, PhD
Frank Hensel, PhD

Frank Hensel, PhD

Board Observer
Frank is Senior Investment Manager at High-Tech Gründerfonds. He brings significant experience in biotechnology, as a scientist and founder of OncoMab GmbH, a spin-off of the University of Würzburg's Institute of Pathology. This expert in tumour-reactive antibodies focuses on the development of biologicals from the manufacturing phase to the clinical-trial stage.
Marc Le Bozec
Marc Le Bozec

Marc Le Bozec

Board Observer
Marc is Equity Portfolio Manager at Financière Arbevel since 2014. He graduated at HEC Business School and started his career at Bossard and Arthur D.Little, Organisation and Strategy Consulting Firms. Since more than 20 years, he developed his expertise in the biotechnologies field and held responsibilities as Executive Director and Entrepreneur at BioProtein, Alfact, Cellectis, CYTOO, Clevexel. Marc also served on the INSERM scientific committee between 2008 and 2016.
Ricardo Castro
Ricardo Castro

Ricardo Castro

Board Observer
Ricardo is an Investment Associate at M Ventures and based in Amsterdam. Before joining M Ventures, Ricardo was working on his PhD degree from Swansea University in collaboration with the Nanomedicine department at the Houston Methodist Research Institute with a focus in nanotechnology and single-cell analysis. Ricardo graduated in Chemical Engineering and has worked as an external consultant and auditor for a broad scope of companies.